Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 12/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HHAT | Q5VTY9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096852 | 0.75 | CA2 (0.32) | CA2HTR1A | |
| SCHEMBL6091848 | 0.75 | CA2 (0.32) | CA2HTR1A | |
| SCHEMBL3646869 | 0.73 | CA2 (0.74) | CA2 | |
| SCHEMBL6093540 | 0.73 | CA2 (0.74) | CA2 | |
| SCHEMBL3614623 | 0.70 | HTR1A (0.35) | HTR1AHHAT | |
| SCHEMBL6086049 | 0.69 | GAA (0.46) | ALDH1A1LMNAGAACA2 | |
| SCHEMBL16385769 | 0.68 | ALDH1A1 (0.52) | ALDH1A1LMNAGAACA2 | |
| SCHEMBL8127095 | 0.68 | ALDH1A1 (0.52) | ALDH1A1LMNAGAACA2 | |
| SCHEMBL4196353 | 0.62 | CA2 (0.54) | LMNACA2 | |
| SCHEMBL13852709 | 0.62 | CA2 (0.54) | LMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813618-B1 | METHOD OF OBTAINING DERIVATIVES OF 4-(N-ALKYLAMINE)-5,6-DIHYDRO-4H-THIENO-[2,3-B]-THIOPYRAN | CRYSTAL PHARMA SAU (ES) | 2013-07-03 | — | — | EP | disclosed |
| US-7030250-B2 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGATIVES, S.L. (ES) | 2006-04-18 | — | — | US | disclosed |
| US-7030250-B2 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGATIVES, S.L. (ES) | 2006-04-18 | — | — | US | disclosed |
| EP-1329453-B1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFONAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | RAGACTIVES SL (ES) | 2004-06-16 | — | — | EP | disclosed |
| EP-1329453-B1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFONAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | RAGACTIVES SL (ES) | 2004-06-16 | — | — | EP | disclosed |
| US-20030220509-A1 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGACTIVES, S.L. | 2003-11-27 | — | — | US | disclosed |
| US-20030220509-A1 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGACTIVES, S.L. | 2003-11-27 | — | — | US | disclosed |
| EP-1329453-A1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | Ragactives, S.L. (ES) | 2003-07-23 | — | — | EP | disclosed |
| EP-1329453-A1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | Ragactives, S.L. (ES) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002020529-A8 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-b)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | RAGA CONSULTORES S L (ES) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002020529-A1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | RAGA CONSULTORES, S.L. (ES) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220509-A1 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | CA7, CA2, CA4 | ALDH1A1 80/4885LMNA 3807/4885GAA 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.